By the numbers: Series A rounds are busting out, platforms are in, M&A is down, valuations surge and 2018 looks wicked big
Every 6 months we seem to get a new round of record numbers for biopharma. And H1 is no exception.
Silicon Valley Bank crunched the financial data for the industry’s first 6 months of the year and came away with some startling conclusions:
These kinds of numbers will only further stoke the debate about whether biopharma is experiencing an intoxicating bubble or entering a new era of therapeutic breakthroughs as Big Pharma becomes increasingly dependent on smaller players for innovation.
But there’s no denying the fact that biotech cash is flowing faster than ever, as the new IPO from Rubius today helps underscore.